CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration

References

• Sanda T, Tyner JW, Gutierrez A, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013;3(5):564–577.
   PubMed Web of Science ®Google Scholar
• Follini E, Marchesini M, Roti G. Strategies to overcome resistance mechanisms in T-Cell acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(12):3021.
   Web of Science ®Google Scholar
• Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134–1142.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011;118(4):874–883.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3398–3406.
   PubMed Web of Science ®Google Scholar
• Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616–3622.
   PubMed Web of Science ®Google Scholar
• Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136–5145.
   PubMed Web of Science ®Google Scholar
• Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479–2483.
   PubMed Web of Science ®Google Scholar
• Delgado-Martin C, Meyer LK, Huang BJ, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568–2576.
   PubMed Web of Science ®Google Scholar
• Liszewski W, Naym DG, Biskup E, et al. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway. Photodermatol Photoimmunol Photomed. 2017;33(3):164–171.
   PubMed Web of Science ®Google Scholar
• Senkevitch E, Durum S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine. 2017;98:33–41.
   PubMed Web of Science ®Google Scholar
• Messina NL, Banks KM, Vidacs E, et al. Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunol Cell Biol. 2013;91(9):556–567.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Mobasher M, Kater AP. Venetoclax-rituximab in chronic lymphocytic leukemia. N Engl J Med. 2018;378(22):2143–2144.
   PubMedGoogle Scholar
• Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074–1087.
   PubMed Web of Science ®Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489(7414):155–159.
   PubMed Web of Science ®Google Scholar
• Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738–3747.
   PubMed Web of Science ®Google Scholar
• Matulis SM, Gupta VA, Nooka AK, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30(5):1086–1093.
   PubMed Web of Science ®Google Scholar
• Zhang M, Mathews Griner LA, Ju W, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci USA. 2015;112(40):12480–12485.
   PubMed Web of Science ®Google Scholar
• Senkevitch E, Li W, Hixon JA, et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. Oncotarget. 2018;9(32):22605–22617.
   PubMedGoogle Scholar
• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043.
   PubMed Web of Science ®Google Scholar
• Jost TR, Borga C, Radaelli E, et al. Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. J Leukocyte Biol. 2016;99:1077–1087.
   PubMed Web of Science ®Google Scholar
• Pitt LA, Tikhonova AN, Hu H, et al. CXCL12-Producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell. 2015;27(6):755–768.
   PubMed Web of Science ®Google Scholar
• Passaro D, Irigoyen M, Catherinet C, et al. CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell. 2015;27(6):769–779.
   PubMed Web of Science ®Google Scholar
• Yao H, Price TT, Cantelli G, et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature. 2018;560(7716):55–60.
   PubMed Web of Science ®Google Scholar
• Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1211–1218.
   PubMed Web of Science ®Google Scholar
• Anderson NM, Harrold I, Mansour MR, et al. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014;28(5):1145–1148.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang LS, Toombs J, et al. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. Nat Cell Biol. 2017;19(10):1226–1236.
   PubMed Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510–3518.
   PubMed Web of Science ®Google Scholar
• Carniti C, Gimondi S, Vendramin A, et al. Pharmacologic Inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res. 2015;21(16):3740–3749.
   PubMed Web of Science ®Google Scholar
• Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128(10):1382–1395.
   PubMed Web of Science ®Google Scholar
• Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017;130(6):789–802.
   PubMed Web of Science ®Google Scholar
• Haile WB, Gavegnano C, Tao S, et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis. 2016;92(Pt B):137–143.
   PubMedGoogle Scholar
• Eisenmann ED, Jin Y, Weber RH, et al. Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1152:122176.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–163.
   PubMed Web of Science ®Google Scholar
• Gianfelici V, Chiaretti S, Demeyer S, et al. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica. 2016;101(8):941–950.
   PubMed Web of Science ®Google Scholar
• Degryse S, de Bock CE, Demeyer S, et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2018;32(3):788–800.
   PubMed Web of Science ®Google Scholar
• Kontro M, Kuusanmaki H, Eldfors S, et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(8):1738–1742.
   PubMed Web of Science ®Google Scholar
• Kuusanmaki H, Leppa AM, Polonen P, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105(3):708–720.
   PubMed Web of Science ®Google Scholar
• Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5(4):1047–1059.
   PubMed Web of Science ®Google Scholar
• Vadillo E, Dorantes-Acosta E, Pelayo R, et al. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. 2018;32(1):36–51.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Devidas M, Cheng SC, et al.; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142–2150.
   PubMed Web of Science ®Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23(1):43–52.
   PubMed Web of Science ®Google Scholar
• Beider K, Nagler A, Wald O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood. 2003;102(6):1951–1958.
   PubMed Web of Science ®Google Scholar
• Hess NJ, Lindner PN, Vazquez J, et al. Different human immune lineage compositions are generated in non-conditioned NBSGW mice depending on HSPC source. Front Immunol. 2020;11:573406.
   PubMed Web of Science ®Google Scholar
• Neves V, Aires-da-Silva F, Corte-Real S, et al. Antibody approaches to treat brain diseases. Trends Biotechnol. 2016;34(1):36–48.
   Web of Science ®Google Scholar